866-997-4948(US-Canada Toll Free)

Epilepsy - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jan 2015

Category :

Diseases & Conditions

No. of Pages : 330 Pages


Global Markets Directs, Epilepsy Pipeline Review, H1 2015, provides an overview of the Epilepsys therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Epilepsy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Epilepsy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Epilepsy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 6
List of Figures 8

Introduction 10
Global Markets Direct Report Coverage 10
Epilepsy Overview 11
Therapeutics Development 12
Pipeline Products for Epilepsy - Overview 12
Pipeline Products for Epilepsy - Comparative Analysis 13
Epilepsy - Therapeutics under Development by Companies 14
Epilepsy - Therapeutics under Investigation by Universities/Institutes 20
Epilepsy - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Epilepsy - Products under Development by Companies 26
Epilepsy - Products under Investigation by Universities/Institutes 35
Epilepsy - Companies Involved in Therapeutics Development 37
Acorda Therapeutics, Inc. 37
Adamas Pharmaceuticals, Inc. 38
Advicenne Pharma 39
Aeolus Pharmaceuticals, Inc. 40
Aestus Therapeutics, Inc. 41
Alexza Pharmaceuticals, Inc. 42
Allergan, Inc. 43
Anavex Life Sciences Corp. 44
Asklepios BioPharmaceutical, Inc. 45
Astellas Pharma Inc. 46
Bial - Portela & Ca, S.A. 47
BioCrea GmbH 48
Bionomics Limited 49
Biovista Inc. 50
Catalyst Pharmaceutical Partners, Inc. 51
Celentyx Ltd. 52
Chong Kun Dang Pharmaceutical Corp. 53
Concert Pharmaceuticals, Inc. 54
Convergence Pharmaceuticals Ltd. 55
D-Pharm Ltd. 56
Desitin Arzneimittel GmbH 57
Eisai Co., Ltd. 58
Epirus Biopharmaceuticals, Inc. 59
Glialogix, Inc. 60
GW Pharmaceuticals plc 61
H. Lundbeck A/S 62
INSYS Therapeutics, Inc. 63
Iproteos S.L. 64
Knopp Biosciences LLC 65
Ligand Pharmaceuticals, Inc. 66
Lipicard Technologies Limited 67
Lohocla Research Corporation 68
Marathon Pharmaceuticals, LLC 69
MarcoPolo Pharmaceuticals SA 70
Marinus Pharmaceuticals, Inc. 71
MedGenesis Therapeutix Inc. 72
Neurocrine Biosciences, Inc. 73
Novartis AG 74
Pfizer Inc. 75
PharmatrophiX, Inc. 76
RestorGenex Corporation 77
Retrophin Inc. 78
Sage Therapeutics 79
Saniona AB 80
SciFluor Life Sciences, LLC 81
SK Biopharmaceuticals Co., Ltd. 82
UCB S.A. 83
Ultragenyx Pharmaceutical Inc. 84
Upsher-Smith Laboratories, Inc. 85
Vichem Chemie Research Ltd. 86
VistaGen Therapeutics, Inc. 87
Zynerba Pharmaceuticals, Inc. 88
Epilepsy - Therapeutics Assessment 89
Assessment by Monotherapy Products 89
Assessment by Target 90
Assessment by Mechanism of Action 95
Assessment by Route of Administration 100
Assessment by Molecule Type 102
Drug Profiles 104
2-DG - Drug Profile 104
ADD-405008 - Drug Profile 106
ADS-8800 Series - Drug Profile 107
ADV-5803 - Drug Profile 108
ADV-6208 - Drug Profile 109
ADV-6769 - Drug Profile 110
ADV-6770 - Drug Profile 111
AEOL-1114B - Drug Profile 112
AEOL-11203 - Drug Profile 113
AEOL-11207 - Drug Profile 114
alprazolam - Drug Profile 116
ANAVEX-2-73 - Drug Profile 118
AV-101 - Drug Profile 119
AVL-5189 - Drug Profile 120
BNP-TLE - Drug Profile 121
brivaracetam - Drug Profile 122
BVA-601 - Drug Profile 124
C-10068 - Drug Profile 125
cannabidiol - Drug Profile 126
carbamazepine - Drug Profile 127
carisbamate - Drug Profile 129
CCG-63802 - Drug Profile 131
Cell Therapy for Parkinson's Disease and Epilepsy - Drug Profile 132
CHEC-9 - Drug Profile 133
CKD-903 - Drug Profile 135
CNV-1061436 - Drug Profile 136
cosyntropin - Drug Profile 137
CPP-115 - Drug Profile 138
CX-1010 - Drug Profile 140
diazepam - Drug Profile 141
diazepam - Drug Profile 142
diazepam - Drug Profile 143
DP-VPA - Drug Profile 145
Drug for Epilepsy - Drug Profile 147
Drug to Agonize GABA Receptor for Epilepsy - Drug Profile 148
Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders - Drug Profile 149
EMSP - Drug Profile 150
Epidiolex - Drug Profile 151
ESB - Drug Profile 153
ESBB - Drug Profile 154
eslicarbazepine acetate - Drug Profile 155
everolimus - Drug Profile 158
fosphenytoin sodium - Drug Profile 163
FV-082 - Drug Profile 164
FV-137 - Drug Profile 165
ganaxolone - Drug Profile 166
Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile 168
GLX-1112 - Drug Profile 169
GWP-42003-P - Drug Profile 170
GWP-42006 - Drug Profile 171
IPR-003 - Drug Profile 172
KM-113 - Drug Profile 173
KM-314 - Drug Profile 174
lacosamide - Drug Profile 175
lamotrigine - Drug Profile 180
levetiracetam - Drug Profile 181
levetiracetam - Drug Profile 184
liatermin - Drug Profile 185
LT-4121 - Drug Profile 188
LT-4122 - Drug Profile 189
LT-4123 - Drug Profile 190
LT-4124 - Drug Profile 191
LT-4125 - Drug Profile 192
LT-4126 - Drug Profile 193
MB-003 - Drug Profile 194
midazolam hydrochloride - Drug Profile 195
MRS-5474 - Drug Profile 196
MSP - Drug Profile 197
naluzotan - Drug Profile 198
NB-23R1 - Drug Profile 199
NGT-168 - Drug Profile 200
P-529 - Drug Profile 201
perampanel - Drug Profile 203
PF-04895162 - Drug Profile 206
PRTT-200 - Drug Profile 207
Remegal - Drug Profile 208
rufinamide - Drug Profile 209
SAGE-217 - Drug Profile 211
SAGE-547 - Drug Profile 212
SAGE-689 - Drug Profile 214
SCT-66 - Drug Profile 215
selurampanel - Drug Profile 216
SF-0034 - Drug Profile 218
SGE-102 - Drug Profile 219
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 220
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 221
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 222
Small Molecule for Central Nervous System - Drug Profile 223
Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile 225
Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy - Drug Profile 226
Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders - Drug Profile 227
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 228
Small Molecules for CNS Disorders - Drug Profile 229
Small Molecules for Epilepsy - Drug Profile 230
Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS - Drug Profile 232
Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile 233
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 234
Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile 236
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 237
Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile 238
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 239
Small Molecules to Inhibit Dynamin for Epilepsy and Oncology - Drug Profile 240
sulthiame - Drug Profile 241
TG-4155 - Drug Profile 242
tonabersat - Drug Profile 243
topiramate - Drug Profile 244
UBP-608 - Drug Profile 245
UX-007 - Drug Profile 246
VAD-1 - Drug Profile 247
VAD-2 - Drug Profile 248
VB-3323 - Drug Profile 249
VID-45110 - Drug Profile 250
VLB-01 - Drug Profile 251
VU-0456810 - Drug Profile 252
YKP-3089 - Drug Profile 253
Z-944 - Drug Profile 255
ZYN-002 - Drug Profile 256
Epilepsy - Recent Pipeline Updates 257
Epilepsy - Dormant Projects 303
Epilepsy - Discontinued Products 309
Epilepsy - Product Development Milestones 311
Featured News & Press Releases 311

Appendix 321
Methodology 321
Coverage 321
Secondary Research 321
Primary Research 321
Expert Panel Validation 321
Contact Us 321
Disclaimer 322

List of Table


Number of Products under Development for Epilepsy, H1 2015 20
Number of Products under Development for Epilepsy - Comparative Analysis, H1 2015 21
Number of Products under Development by Companies, H1 2015 23
Number of Products under Development by Companies, H1 2015 (Contd..1) 24
Number of Products under Development by Companies, H1 2015 (Contd..2) 25
Number of Products under Development by Companies, H1 2015 (Contd..3) 26
Number of Products under Development by Companies, H1 2015 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2015 29
Comparative Analysis by Late Stage Development, H1 2015 30
Comparative Analysis by Clinical Stage Development, H1 2015 31
Comparative Analysis by Early Stage Development, H1 2015 32
Comparative Analysis by Unknown Stage Development, H1 2015 33
Products under Development by Companies, H1 2015 34
Products under Development by Companies, H1 2015 (Contd..1) 35
Products under Development by Companies, H1 2015 (Contd..2) 36
Products under Development by Companies, H1 2015 (Contd..3) 37
Products under Development by Companies, H1 2015 (Contd..4) 38
Products under Development by Companies, H1 2015 (Contd..5) 39
Products under Development by Companies, H1 2015 (Contd..6) 40
Products under Development by Companies, H1 2015 (Contd..7) 41
Products under Development by Companies, H1 2015 (Contd..8) 42
Products under Investigation by Universities/Institutes, H1 2015 43
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 44
Epilepsy - Pipeline by Acorda Therapeutics, Inc., H1 2015 45
Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 46
Epilepsy - Pipeline by Advicenne Pharma, H1 2015 47
Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 48
Epilepsy - Pipeline by Aestus Therapeutics, Inc., H1 2015 49
Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H1 2015 50
Epilepsy - Pipeline by Allergan, Inc., H1 2015 51
Epilepsy - Pipeline by Anavex Life Sciences Corp., H1 2015 52
Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2015 53
Epilepsy - Pipeline by Astellas Pharma Inc., H1 2015 54
Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H1 2015 55
Epilepsy - Pipeline by BioCrea GmbH, H1 2015 56
Epilepsy - Pipeline by Bionomics Limited, H1 2015 57
Epilepsy - Pipeline by Biovista Inc., H1 2015 58
Epilepsy - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 59
Epilepsy - Pipeline by Celentyx Ltd., H1 2015 60
Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 61
Epilepsy - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 62
Epilepsy - Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 63
Epilepsy - Pipeline by D-Pharm Ltd., H1 2015 64
Epilepsy - Pipeline by Desitin Arzneimittel GmbH, H1 2015 65
Epilepsy - Pipeline by Eisai Co., Ltd., H1 2015 66
Epilepsy - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 67
Epilepsy - Pipeline by Glialogix, Inc., H1 2015 68
Epilepsy - Pipeline by GW Pharmaceuticals plc, H1 2015 69
Epilepsy - Pipeline by H. Lundbeck A/S, H1 2015 70
Epilepsy - Pipeline by INSYS Therapeutics, Inc., H1 2015 71
Epilepsy - Pipeline by Iproteos S.L., H1 2015 72
Epilepsy - Pipeline by Knopp Biosciences LLC, H1 2015 73
Epilepsy - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 74
Epilepsy - Pipeline by Lipicard Technologies Limited, H1 2015 75
Epilepsy - Pipeline by Lohocla Research Corporation, H1 2015 76
Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H1 2015 77
Epilepsy - Pipeline by MarcoPolo Pharmaceuticals SA, H1 2015 78
Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 79
Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H1 2015 80
Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H1 2015 81
Epilepsy - Pipeline by Novartis AG, H1 2015 82
Epilepsy - Pipeline by Pfizer Inc., H1 2015 83
Epilepsy - Pipeline by PharmatrophiX, Inc., H1 2015 84
Epilepsy - Pipeline by RestorGenex Corporation, H1 2015 85
Epilepsy - Pipeline by Retrophin Inc., H1 2015 86
Epilepsy - Pipeline by Sage Therapeutics, H1 2015 87
Epilepsy - Pipeline by Saniona AB, H1 2015 88
Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H1 2015 89
Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 90
Epilepsy - Pipeline by UCB S.A., H1 2015 91
Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2015 92
Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 93
Epilepsy - Pipeline by Vichem Chemie Research Ltd., H1 2015 94
Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H1 2015 95
Epilepsy - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 96
Assessment by Monotherapy Products, H1 2015 97
Number of Products by Stage and Target, H1 2015 99
Number of Products by Stage and Mechanism of Action, H1 2015 104
Number of Products by Stage and Route of Administration, H1 2015 109
Number of Products by Stage and Molecule Type, H1 2015 111
Epilepsy Therapeutics - Recent Pipeline Updates, H1 2015 265
Epilepsy - Dormant Projects, H1 2015 311
Epilepsy - Dormant Projects (Contd..1), H1 2015 312
Epilepsy - Dormant Projects (Contd..2), H1 2015 313
Epilepsy - Dormant Projects (Contd..3), H1 2015 314
Epilepsy - Dormant Projects (Contd..4), H1 2015 315
Epilepsy - Dormant Projects (Contd..5), H1 2015 316
Epilepsy - Discontinued Products, H1 2015 317
Epilepsy - Discontinued Products (Contd..1), H1 2015 318

List of Chart


Number of Products under Development for Epilepsy, H1 2015 20
Number of Products under Development for Epilepsy - Comparative Analysis, H1 2015 21
Number of Products under Development by Companies, H1 2015 22
Number of Products under Investigation by Universities/Institutes, H1 2015 28
Comparative Analysis by Late Stage Development, H1 2015 30
Comparative Analysis by Clinical Stage Development, H1 2015 31
Comparative Analysis by Early Stage Products, H1 2015 32
Assessment by Monotherapy Products, H1 2015 97
Number of Products by Top 10 Targets, H1 2015 98
Number of Products by Stage and Top 10 Targets, H1 2015 98
Number of Products by Top 10 Mechanism of Actions, H1 2015 103
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 103
Number of Products by Top 10 Routes of Administration, H1 2015 108
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 109
Number of Products by Top 10 Molecule Types, H1 2015 110
Number of Products by Stage and Top 10 Molecule Types, H1 2015 110

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *